Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients

Reuters

Aug 30

Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients

Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2563113885"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563113885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563113885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-30 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563113885","market":"nz","top_or_hot":-1,"title":"Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-30 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250830:nNDL3BrCN4:1","article_id":"2563113885","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563113885","pubTimestamp":1756557014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amarin Corporation Announces New REDUCE-IT Analyses Showing VASCEPA/VAZKEPA Therapy Reduces Cardiovascular Risk in High-Risk Patients. Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA/VAZKEPA  on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","AMRN":"阿玛琳","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Amarin Corporation宣布推出新的REDUCE-IT®分析显示VASCEPA®/瓦兹凯帕®治疗降低高危患者的心血管风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":0.9,"NDAQ":0.9},"content_text":"Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    \n\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}